Trials / Completed
CompletedNCT06680349
Two Anti-CD20 Regimens for Fibrillary Glomerulonephritis
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- University of Turin, Italy · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to evaluate the clinical and histological effects of two rituximab-based regimens in fibrillary glomerulonephritis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anti-CD20 antibodies | comparing anti-CD20 (lymphoma protcol, RTX 375 mg/m2 every 4 weeks ) alone Vs. Intensive B-cell depletion therapy (IBCDT) which is based on the combination of RTX (given at the dose of 375 mg/m2 every 4 weeks followed by 2 additional doses after 1 and 2 months), cyclophosphamide (two pulses of 10 mg/kg, corrected according to renal function, on days 4 and 17) and methylprednisolone (three bolus doses of 15 mg/kg) followed by oral prednisone (starting dose 50 mg tapered until complete discontinuation in 4 months). |
Timeline
- Start date
- 2022-12-01
- Primary completion
- 2024-01-02
- Completion
- 2024-01-02
- First posted
- 2024-11-08
- Last updated
- 2024-11-08
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT06680349. Inclusion in this directory is not an endorsement.